MSD Korea’s antibody, Zerbaxa’s approval in Korea

Published: 2017-04-20 16:28:00
Updated: 2017-04-20 13:35:22

‘Zerbaxa(generic name: ceftolozane+tazobactam),’ a MSD Korea’s(CEO Avi BenShoshan) new antibody, acquired sales approval in Korea. On the 7th, the Ministry of Food and Drug Safety(MFDS) approved the Zerbaxa’s commercialization as a combination therapy with metronidazole for the treatment of compl...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.